Literature DB >> 15964955

Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42).

In-Kyu Yoon1, Evelina Angov, David Larson, D Gray Heppner, James F Cummings, V Ann Stewart.   

Abstract

Volunteers vaccinated with a candidate malaria vaccine containing merozoite surface protein 1(42) (MSP-1(42)) exhibit antibodies to MSP-1(42) that are measured by enzyme-linked immunosorbent assay (ELISA). The purpose of this study was to make a human reference standard for MSP-1(42) antibody measured in absolute quantity units using pooled plasma samples known to contain high titers of MSP-1(42) antibody based on previous ELISA results. Immobilized metal affinity chromatography was used to determine the amount of MSP-1(42) antibody in this plasma pool. Hexahistidine-tagged MSP-1(42) antigen adsorbed to nickel-chelating resin was used to capture MSP-1(42) antibody from the plasma pool. The intact MSP-1(42) antibody-antigen complexes were eluted and total IgG was measured by an ELISA standardized against purified human IgG. In this way, the human reference standard was determined to contain 48.3 microg/mL of MSP-1(42) antibody. This reference standard may be useful as a quantitative working standard for measuring MSP-1(42) antibody response in future vaccine clinical trials involving MSP-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964955

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Samuel E Moretz; Michael P Fay; Louis H Miller; Laura B Martin; Mark A Pierce; Ruth D Ellis; Gregory E D Mullen; Carole A Long
Journal:  Clin Vaccine Immunol       Date:  2009-05-13

2.  Plasmodium falciparum infection during suppressive prophylaxis with mefloquine does not induce an antibody response to merozoite surface protein-1(42).

Authors:  James E Moon; Gregory A Deye; Lori Miller; Susan Fracisco; R Scott Miller; Donna Tosh; James F Cummings; Colin Ohrt; Alan J Magill
Journal:  Am J Trop Med Hyg       Date:  2011-05       Impact factor: 2.345

3.  Serological Profiling for Malaria Surveillance Using a Standard ELISA Protocol.

Authors:  Linda M Murungi; Rinter K Kimathi; James Tuju; Gathoni Kamuyu; Faith H A Osier
Journal:  Methods Mol Biol       Date:  2019

4.  Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Authors:  Michele D Spring; James F Cummings; Christian F Ockenhouse; Sheetij Dutta; Randall Reidler; Evelina Angov; Elke Bergmann-Leitner; V Ann Stewart; Stacey Bittner; Laure Juompan; Mark G Kortepeter; Robin Nielsen; Urszula Krzych; Ev Tierney; Lisa A Ware; Megan Dowler; Cornelus C Hermsen; Robert W Sauerwein; Sake J de Vlas; Opokua Ofori-Anyinam; David E Lanar; Jack L Williams; Kent E Kester; Kathryn Tucker; Meng Shi; Elissa Malkin; Carole Long; Carter L Diggs; Lorraine Soisson; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; D Gray Heppner
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

5.  Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

Authors:  Bernhards R Ogutu; Odika J Apollo; Denise McKinney; Willis Okoth; Joram Siangla; Filip Dubovsky; Kathryn Tucker; John N Waitumbi; Carter Diggs; Janet Wittes; Elissa Malkin; Amanda Leach; Lorraine A Soisson; Jessica B Milman; Lucas Otieno; Carolyn A Holland; Mark Polhemus; Shon A Remich; Christian F Ockenhouse; Joe Cohen; W Ripley Ballou; Samuel K Martin; Evelina Angov; V Ann Stewart; Jeffrey A Lyon; D Gray Heppner; Mark R Withers
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.